Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07238478

JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women

Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of JDS-HF3.0 in Menopause Related Quality of Life Outcomes in Postmenopausal Women

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
250 (estimated)
Sponsor
Bonafide Health · Industry
Sex
Female
Age
50 Years – 70 Years
Healthy volunteers
Accepted

Summary

The goal of this interventional study is to evaluate whether the study product can help improve quality of life and reduce common menopause symptoms-such as joint discomfort, hot flashes and night sweats-in women aged 50-70. The primary research question is whether taking the study product daily for 12 weeks can reduce the severity and frequency of menopause-related symptoms.

Detailed description

About 250 women across the U.S. will take part in this study. Participants will be randomly placed into one of two groups-one will take the active study product, and the other will take a placebo. All participants will take two tablets each morning for about 12 weeks. The total time the participant will be in the study is about 14 weeks, including the time it takes to collect baseline values. All parts of the study are done virtually, in-person visits are not required. The participant will take part in five virtual check-ins, including a screening visit, a baseline visit, two check-ins during the study, and a final visit at the end. Throughout the study, the participant will be asked to complete daily diaries and weekly and monthly questionnaires to report on their symptoms and how they are feeling. These will include questions about hot flashes, night sweats, physical comfort, and overall well-being. The study is led by a research team based in Harrison, NY, USA.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTJDS-HF3.0Active Supplement JDS-HF3.0
OTHERPlaceboNonactive Placebo

Timeline

Start date
2025-05-14
Primary completion
2026-07-01
Completion
2026-10-01
First posted
2025-11-20
Last updated
2025-11-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT07238478. Inclusion in this directory is not an endorsement.